Investigation of the Inhibitory Effect of Simvastatin on the Metabolism of Lidocaine Both in vitro and in vivo

Ying Wang, Qiugeng Ou-yang, Wanli Huang, Huan-le Huang, Xinlei Zhuang, Qianmeng Lin, Dalili Zeng

Pharmacy Department, Ningbo Medical Center Lihuili Hospital, Ningbo 315000, Zhejiang Province, People’s Republic of China; School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou 325035, Zhejiang Province, People’s Republic of China; School of Laboratory Medicine and Life Science, Wenzhou Medical University, Wenzhou 325035, Zhejiang Province, People’s Republic of China; Department of Pharmacy, Ruian Hospital of Traditional Chinese Medicine, Wenzhou 325000, Zhejiang Province, People’s Republic of China

Background: Lidocaine has cardiovascular and neurologic toxicity, which is dose-dependent. Due to CYP3A4-involved metabolism, lidocaine may be prone to drug–drug interactions.

Materials and Methods: Given statins have the possibility of combination with lidocaine in the clinic, we established in vitro models to assess the effect of statins on the metabolism of lidocaine. Further pharmacokinetic alterations of lidocaine and its main metabolite, monoethylglycinexylidide in rats influenced by simvastatin, were investigated.

Results: In vitro study revealed that simvastatin, among the statins, had the most significant inhibitory effect on lidocaine metabolism with IC50 of 39.31 µM, 50 µM and 15.77 µM for RLM, HLM and CYP3A4.1, respectively. Consistent with in vitro results, lidocaine concomitantly used with simvastatin in rats was associated with 1.2-fold AUC(0-∞), and 20%-decreased clearance for lidocaine, and 1.4-fold Cmax for MEGX compared with lidocaine alone.

Conclusion: Collectively, these results implied that simvastatin could evidently inhibit the metabolism of lidocaine both in vivo and in vitro. Accordingly, more attention and necessary therapeutic drug monitoring should be paid to patients with the concomitant coadministration of lidocaine and simvastatin so as to avoid unexpected toxicity.

Keywords: lidocaine, simvastatin, drug–drug interaction, pharmacokinetics, in vitro model

Introduction
Lidocaine, an antiarrhythmic drug, is widely used to treat ventricular arrhythmias, especially in patients with acute myocardial infarction or cardiac surgery.1–5 Lidocaine is accompanied by serious adverse effects, which are primarily divided into two categories, cardiovascular and neurologic.1 Compared to cardiovascular toxicity, the occurrence of neurologic toxicity is more frequent and significant, which is dose-dependent.1 Patients may experience numbness, dizziness and light-headedness even when lidocaine is administrated at a therapeutic dose, while seizures, muscular spasms, visual disturbances, hallucinations, confusion and agitation may occur when the lidocaine plasma concentration is above the normal level.1,6 Consequently, therapeutic drug monitoring may be recommended when lidocaine is applied in the clinic.

Previous studies have revealed that lidocaine is primarily metabolized by CYP3A4 to form monoethylglycinexylidide (MEGX), whose potency is lower than lidocaine but cardiovascular and neurologic toxicity is parallel to lidocaine.7–15
Because of CYP-based metabolism, lidocaine may be prone to drug–drug interactions, which means its pharmacokinetic and pharmacodynamic response would be altered when co-administrated with CYP3A4 modulators.

In patients with hyperlipemia, the accumulation of fatty in the intima of arteries would increase the risk of coronary atherosclerosis, and the latter is highly associated with ventricular arrhythmias, which indicates patients may take statins (such as simvastatin) and lidocaine simultaneously. It’s reported that simvastatin is mainly metabolized by CYP3A4/5 and can inhibit CYP3A activity. An in vitro study exhibited that simvastatin could competitively inhibit the metabolism of midazolam (a CYP3A4 substrate) with Ki at 10 μM, and an in vivo study showed that co-administration with simvastatin resulted in 1.42-fold increment of AUC (0-t) and 1.96-fold prolongation of t1/2 for sinomenine (a CYP3A4 substrate). Therefore, there may be a drug–drug interaction between lidocaine and simvastatin.

In this study, we established several in vitro models to assess the effects of other statins on the metabolism of lidocaine compared with that of simvastatin, and further investigated the potential drug–drug interaction between lidocaine and simvastatin in rats. Moreover, the impacts of simvastatin on lidocaine metabolism in rat/human liver microsome and recombinant human CYP3A4.1 microsome were identified.

Materials and Methods

Chemical and Reagents

Lidocaine, simvastatin and bupivacaine (served as internal standard, IS) were purchased from Beijing Sunflower and Technology Development Co., Ltd (Beijing, China) and MEGX was from Toronto Research Chemicals Inc (Toronto, Ontario, Canada). Lidocaine hydrochloride for subcutaneous administration to rats was purchased from Shandong Hualu Pharmaceutical Co., Ltd (Shandong, China). Phosphate buffer saline (PBS) and the reduced nicotinamide adenine dinucleotide phosphate (NADPH) were bought from Beyotime Biotechnology (Shanghai, China) and Roche Pharmaceutical Ltd. (Basel, Switzerland), respectively. Pooled rat/human liver microsome (RLM/HLM) were from Corning Life Sciences Co., Ltd (Wujiang, China), while recombinant human CYP3A4.1 protein and cytochrome b5 were kind gifts from Beijing Hospital (Beijing, China). Acetonitrile was purchased from Merck (Darmstadt, Germany) and formic acid was from Sigma-Aldrich Co. (St. Louis, MO, USA), both of which were of analytical grade.

Equipment and Operation Conditions

An Acquity UPLC-MS/MS system (Waters Corp., Milford, MA, USA) was employed for the isolation of lidocaine, MEGX and bupivacaine. These analytes were chromatographed on an Acquity BEH C18 column (2.1 mm×50 mm, 1.7 μm) at 40°C using a mobile phase consisting of acetonitrile and water (0.1% formic acid) with a gradient elution program at a flow rate of 0.4 mL/min (Table 1). The multiple-reaction-monitoring (MRM) transitions in a positive mode were used to quantify these analytes and their corresponding monitored transitions and parameters are displayed in Table 2.

In vitro Kinetic Parameters for Lidocaine in RLM/HLM

The in vitro models selected in our study included RLM and HLM. The 200-μL RLM/HLM incubation system consisted of lidocaine, 0.5mg/mL RLM or 0.2mg/mL HLM, 100 mmol PBS (pH 7.4) and 1 mM NADPH. To confirm the Km value, the concentrations of lidocaine were designed at 10-1000 μM for RLM and 100–3000 μM for HLM. After 5-min preincubation at 37°C, 1 mM NADPH was added to initiate the reaction. After 40-min incubation,
the incubation system was frozen at −80°C to stop the reaction. After the addition of 400 µL of acetonitrile and 20 µL of bupivacaine (50 µg/mL), the incubation system was suffered from 2-min vortex and 10-min centrifugation at 13,000 rpm, and a 20 µL aliquot of the supernatant was diluted with 1 mL ultra-pure water then for UPLC-MS/MS analysis. All samples were performed in triplicate.

Comparison of Inhibitory Effects Between Simvastatin and Other Statins in RLM/HLM

The in vitro models selected in our study included RLM and HLM. The 200-µL incubation system contained lidocaine (250 µM for RLM and 1000 µM for HLM, based on their own Km values), RLM (0.5mg/mL) or HLM (0.2mg/mL), and 1 mM NADPH in 100 mmol PBS (pH 7.4) with/without the presence of statins (100 µM). The following processing steps were the same as the above experiments.

Inhibitory Effect of Simvastatin on Lidocaine in RLM, HLM and CYP3A4.1

The in vitro models selected in our study included RLM, HLM and recombinant CYP3A4 enzyme. The CYP3A4.1 incubation system referred to our previous study.25 The 200-µL incubation system contained lidocaine (250 µM for RLM, 1000 µM for HLM and 500 µM for CYP3A4.1, based on their own Km values), RLM (0.5mg/mL) or HLM (0.2mg/mL) or CYP3A4.1 (5pmol) coupled with b5 (5pmol), and 1 mM NADPH in 100 mmol PBS (pH 7.4) with the presence of simvastatin (0, 0.01, 0.1, 1, 10, 25, 50 and 100µM). The following processing steps were the same as the above experiments.

Inhibitory Effect of Simvastatin on Lidocaine in Rats

Male Sprague–Dawley rats (180–200 g) were obtained from Shanghai Laboratory Animal Center and maintained in the Laboratory Animal Center of Wenzhou Medical University in a temperature-controlled environment with a 12 h light-dark cycle. Animals had free access to standard laboratory food and tap water. All experiments were performed after the approval of the Animal Care and Use Committee of Wenzhou Medical University (Wenzhou, China, License No. WYDW [ZJ] 2019–0002) and followed the Guide for the Care and Use of Laboratory Animal.

Before the experiments, rats were fasted for 12 h but free to water. 8 mg/mL lidocaine hydrochloride with normal saline. Simvastatin was dissolved in 0.5% Carboxymethylcellulose sodium salt solution to achieve a concentration at 20 mg/mL. Twelve rats were randomly divided into two groups (n=6): control group (group A, lidocaine alone) and study group (group B, lidocaine and simvastatin). 40 mg/kg simvastatin was orally pretreated to group B and an equivalent volume of 0.5% CMC-Na solution was orally pretreated to group A. 30 minutes later, 10 mg/kg lidocaine was administrated subcutaneously to the two groups. Simvastatin has been reported to have an inhibitory effect on CYP3A4 and lidocaine has been identified as a substrate of CYP3A4, which means simvastatin may be a mechanism-based inhibitor for lidocaine. Therefore, it is recommended that the administration of simvastatin was half an hour earlier than that of lidocaine to maximize the effect of the potential interaction.24–28 Subsequently, the blood samples (ca. 0.3 mL) were collected from the tail vein into tubes containing sodium heparin at 0.083, 0.167, 0.25, 0.5, 1, 2, 4, 6, 8, 10, 12 and 24 h after the administration of lidocaine. The collected sample was processed by centrifugation (13,000 rpm for 10 min), the 100-µL plasma was mixed with 20µL of bupivacaine (100 ng/mL) and 400µL of acetonitrile, the mixture was stirred for 2 min and centrifuged at 13,000 rpm for 15 min, and a 50µL aliquot of the supernatant was diluted with 200µL of ultra-pure water then for UPLC-MS/MS analysis.

Statistical Analysis

The in vitro kinetic parameters and the IC50 values were calculated with GraphPad Prism 5.0 (Graphpad Software Inc., San Diego, CA, USA) by Michaelis-Menten analysis and log(inhibitor) vs normalized response analysis, respectively. Pharmacokinetic profiles in rats were analyzed by noncompartmental methods using DAS software (Version 3.0, Bontz Inc., Beijing, China) and the concentration–time curves were depicted using Origin 8.0 (Originlab Company, Northampton, MA, USA). The main pharmacokinetic profiles between group A and group B were statistically analyzed by unpaired t-test analysis using GraphPad Prism 5.0. P<0.05 meant statistical significance.

Results

UPLC-MS/MS

The representative chromatograms of lidocaine, MEGX and bupivacaine in blank plasma (A), blank plasma spiked with analytes (B), and plasma at 2 h after the administration of lidocaine (C) are displayed in Figure 1. Although some interfering peaks are observed at the elution time of the
Figure 1 UPLC-MS/MS chromatographs of lidocaine, monoethyglycinexilidide (MEGX) and bupivacaine. (A) Blank plasma sample. (B) Blank plasma spiked with 200 ng/mL lidocaine, 0.5 ng/mL MEGX and 100 ng/mL bupivacaine. (C) Simvastatin-treated rat plasma sample at 2 h after the administration of lidocaine.
two analytes and bupivacaine in a blank plasma sample, their responses were less than 20% of the responses of the LLOQ sample for lidocaine and MEGX, and 5% for bupivacaine. Bupivacaine did not affect the measurement of the two analytes. Additionally, there was no carry-over effect. The concentrations of calibration curves were set at 10–2000 ng/mL for lidocaine and 0.1–50 ng/mL for MEGX, respectively. The concentrations of quality control samples were set at 10, 20, 800 and 1600 ng/mL for lidocaine, and 0.1, 0.2, 20 and 40 ng/mL for MEGX, respectively, all of which were validated according to FDA and EMEA guidelines for bioanalytical validation. They were within the acceptable limits and their corresponding data about accuracy, precision, recovery, matrix effect and stability are presented in supplementary Tables 1–3.

In vitro Kinetic Parameters for Lidocaine in RLM/HLM

In RLM, the Michaelis-Menten curve of lidocaine is plotted in Figure 2(A) and its kinetic parameters were calculated, in which $V_{\text{max}}$ value was $8.858 \pm 0.037$ nmol/min/mg and $K_m$ value was $216.750 \pm 1.344$ µM. In HLM, the Michaelis-Menten curve is depicted in Figure 2(B), and $V_{\text{max}}$ and $K_m$ values were calculated at $5.21 \pm 0.04$ nmol/min/mg and $1027.50 \pm 16.26$ µM, respectively.

Effects of Simvastatin and Other Statins on the Metabolism of Lidocaine in vitro

The results of the comparison of inhibitory effects on lidocaine between simvastatin and other statins (lovastatin, rosuvastatin and atorvastatin) are exhibited in Figure 3. Simvastatin inhibited the metabolism of lidocaine to 21.97% in RLM and 16.58% in HLM, while lovastatin, rosuvastatin and atorvastatin inhibited to 54.42%, 93.91% and 89.74% in RLM, and 56.05%, 96.33% and 97.96% in HLM, respectively. These results manifested that the inhibition by simvastatin was most significant and the outcomes in RLM and HLM were consistent, indicating the combination of lidocaine and simvastatin might have a high likelihood of drug–drug interaction.

The IC$_{50}$ curves of simvastatin on the metabolism of lidocaine in RLM, HLM and CYP3A4.1 are displayed in Figure 4 and the corresponding IC$_{50}$ values were 39.31 µM, 50 µM, and 15.77 µM, respectively. When the concentration of simvastatin was 100 µM, lidocaine metabolism was inhibited by 78.03%, 83.42% and 74% in RLM, HLM and CYP3A4.1, respectively.

Effects of Simvastatin on the Metabolism of Lidocaine in vivo

The concentration–time curves of lidocaine and MEGX are shown in Figure 5 and their corresponding pharmacokinetic parameters were shown in Tables 3 and 4. In comparison with the control group, lidocaine exposure in the study group was enhanced with 1.2-fold AUC$_{(0-t)}$ (P<0.05) and 1.2-fold AUC$_{(0-\infty)}$ (P<0.05), and its clearance was decreased with CL$_{z/F}$ value from $4.143 \pm 0.715$ L/h/kg to $3.370 \pm 0.419$ L/h/kg (P<0.05). MEGX exposure was also increased with C$_{\text{max}}$ value from $25.032 \pm 6.101$ ng/mL to $33.799 \pm 6.788$ ng/mL, approximately 1.4-fold increment. Besides, there is no significant difference among other pharmacokinetic parameters between the control group and the study group (P>0.05).

Figure 2 Michaelis-Menten curves for lidocaine in rat liver microsome (RLM), (A) and human liver microsome (HLM). (B) Values are the mean ± SD, N=3.
Discussion

The clinical use of lidocaine may result in cardiotoxicity and neurotoxicity, and the latter is related to dose, which implies the higher lidocaine plasma concentration would be more likely to induce neurotoxicity.\textsuperscript{1,6} As the involvement of CYP3A4, the metabolism of lidocaine is susceptible to other drugs, with a high risk of potential interactions and adverse reactions.

Several in vitro models are usually employed for metabolic researches, including liver slices, liver microsomes, hepatocyte and recombinant enzyme.\textsuperscript{31,32} It is higher-throughput, more rapid and sensitive with less interference factors compared with in vivo models.\textsuperscript{21} Accordingly, we established RLM and HLM incubation systems to obtain the in vitro kinetic parameters for lidocaine and to study the combination of lidocaine with statins that may be co-administrated with lidocaine in the clinic. The in vitro results showed that simvastatin could significantly inhibit lidocaine metabolism with IC\textsubscript{50} of 39.31 µM in RLM, which underlay the potential interaction between lidocaine and simvastatin in rats. The IC\textsubscript{50} value of 50 µM in HLM meant the results obtained in rats might be extrapolated to human to some extent. Further inhibition in CYP3A4.1 with IC\textsubscript{50} of 15.77 µM elucidated lidocaine metabolism inhibited by simvastatin was mainly via CYP3A4.

Consistent with in vitro results, the metabolism of lidocaine inhibited by simvastatin also occurred in rats. Lidocaine plasma concentrations were obviously increased and the clearance was evidently decreased, which may be explained by the inhibition of CYP3A4 activity. It is reported
that simvastatin could competitively inhibit the metabolism of midazolam (a CYP3A4 substrate) with Ki at 10 μM.20 Besides, when co-administrated with simvastatin, simonene (a CYP3A4 substrate) experienced 1.42-fold increment of AUC0–t and 1.96-fold prolongation of t1/2, while apatinib (a CYP3A4 substrate) achieved 2.4-fold increment of AUC0–t and 73.9% decrement of CLz/F.20,33 Therefore, simvastatin could inhibit the activity of CYP3A4 enzyme, impairing the metabolism and excretion of lidocaine in rats, thereby resulting in pharmacokinetic alterations in terms of AUC0–t, AUC0–∞ and CLz/F. Additionally, the absorption of lidocaine was not affected by simvastatin as evidenced by Cmax value of lidocaine presenting no remarkable difference, which may be due to lidocaine administrated by subcutaneous injection rather than gavage.

Apart from CYP3A4, CYP1A2 also played an indispensable role in lidocaine metabolism.14 However, CYP1A2 may have no responsibility for the interaction between lidocaine and simvastatin. Simvastatin was metabolized by CYP3A4/5 (≥80%) and CYP2C8 (≥20%), while CYP1A2, CYP2D6, CYP2C19, CYP2C9 and other CYP isoforms were not involved, which implied that simvastatin had no affinity for CYP1A2 and thereby had no inhibitory effect on CYP1A2 activity.35 Meanwhile, there had been no researches ever reported about the inhibition of simvastatin on CYP1A2 other than CYP3A4. Thus, the drug–drug interaction between lidocaine and simvastatin may involve CYP3A4 only without the participation of CYP1A2.

MEGX, formed by lidocaine N-dealkylation in human liver, also possessed the potential of antiarrhythmic and local anesthesia lower than lidocaine as well as the risk of cardiovascular and neurologic toxicity parallel to lidocaine.13–15 Therefore, MEGX pharmacokinetics was also studied. After the administration of simvastatin, Cmax value of MEGX exhibited a 1.4-fold increment compared with lidocaine administrated alone. This increment was most likely due to that lidocaine metabolism and excretion, affected by simvastatin, were impaired, thereby leading to enhanced lidocaine exposure and prolonged retention time, which inferred lidocaine had more chances to form MEGX. Additionally, MEGX could be further metabolized to glycinexylidide, which may be inhibited by simvastatin and then caused the increased Cmax value.36

In conclusion, simvastatin can inhibit the metabolism of lidocaine both in vitro and in vivo, affect the pharmacokinetics of lidocaine and MEGX in rats, and may trigger pharmacodynamic alteration and side effects. Lidocaine neurotoxicity is dose-dependent, meaning the higher lidocaine plasma concentration could increase the risk of neurotoxicity. Thus, this study is full of clinically guiding significance to the concomitant use of lidocaine and simvastatin. When these two drugs are taken concurrently, more attention and necessary therapeutic drug monitoring should be paid in order to reduce the lidocaine-related side events.

**Acknowledgments**

The authors appreciate the School of Pharmaceutical Sciences, Wenzhou Medical University.

**Disclosure**

The authors report no conflicts of interest in this work.

**References**

1. Samarin MJ, Mohrien KM, Oliphant CS. Continuous intravenous antiarrhythmic agents in the intensive care unit: strategies for safe and effective use of amiodarone, lidocaine, and procainamide. Crit Care Nurs Q. 2015;38(4):329–344. doi:10.1097/CNQ.0000000000000082
2. Malone E, Ensink J, Turner T, et al. Intravenous continuous infusion of lidocaine for treatment of equine ileus. Vet Surg. 2006;35(1):60–66. doi:10.1111/j.1532-950X.2005.00113.x

3. Solis CND, Iii MK. Serum concentrations of lidocaine and its metabolites MEGX and GX during and after prolonged intravenous infusion of lidocaine in horses after colic surgery. J Equine Vet Sci. 2007;27(9):398–404. doi:10.1016/j.jevs.2007.07.007

4. Rezende ML, Wagner AE, Mama KR, Ferreira TH, Steffey EP. Effects of intravenous administration of lidocaine on the minimum alveolar concentration of sevoflurane in horses. Am J Vet Res. 2011;72(4):446–451. doi:10.2460/ajvr.72.4.446

5. Wagner AE, Mama KR, Ferreira TH, Rezende ML. Comparison of the cardiovascular effects of equipotent anesthetic doses of sevoflurane alone and sevoflurane plus an intravenous infusion of lidocaine in horses. Am J Vet Res. 2011;72(4):452–460. doi:10.2460/ajvr.72.4.452

6. Rademaker AW, Kellen J, Tam YK, Wyse DG. Character of adverse effects of prophylactic lidocaine in the coronary care unit. Clin Pharmacol Ther. 1986;40(1):71–80. doi:10.1038/clpt.1986.141

7. Hermannson J, Glaumann H, Karlén B, Von BC. Metabolism of lidocaine in human liver in vitro. Basic Clin Pharmacol Toxicol. 2010;47:49–52.

8. Imaoka S, Enomoto K, Oda Y, et al. Lidocaine metabolism by human cytochrome P-450s purified from hepatic microsomes: comparison of those with rat hepatic cytochrome P-450s. J Pharmac Exp Ther. 1990;255:1385–1391.

9. Baggetzi MJ, Aoyama T, Gonzalez EF, Meyer UA. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European atherosclerosis society. Eur Heart J. 2013;34(45):3478–3490. doi:10.1093/eurheartj/eht273

10. Libby P, Buring JE, Badimon L, et al. Atherosclerosis. Nat Rev Dis Primers. 2019;5(1):56. doi:10.1038/s41572-019-0106-z

11. Herrington W, Lacey B, Sherlaker P, Armitage J, Lewington S. Epidemiology of atherosclerosis and the potential to reduce the global burden of atherothrombotic disease. Circ Res. 2016;118(4):535. doi:10.1161/CIRCRESAHA.115.307611

12. Goldstein J, Brown M. A century of cholesterol and coronaries: from plagues to genes to statins. Cell. 2015;161(1):161–172. doi:10.1016/j.cell.2015.01.036

13. Nordeostgaard BRG, John M, Humphries C, et al. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European atherosclerosis society. Eur Heart J. 2013;34(45):3478–3490. doi:10.1093/eurheartj/eht273

14. Wang et al. 2019. Nordestgaard BRG, John M, Humphries C, et al. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European atherosclerosis society. Eur Heart J. 2013;34(45):3478–3490. doi:10.1093/eurheartj/eht273

15. Oni G, Brown S, Burrus C, et al. Effect of 4% topical lidocaine applied to the face on the serum levels of lidocaine and its metabolite, monoethylglycine xylide. J Aesthetic Clin Pharmacol. 2012;28(2):200–204. doi:10.1016/j.jacp.2011.01.008

16. Lambertz CK, Johnson CJ, Montgomery PG, Maxwell JR, Fry SJ. Toxicity of topical lidocaine applied to the breasts to reduce discomfort during screening mammography. J Aesthetic Clin Pharmacol. 2012;28(2):200–204. doi:10.1016/j.jacp.2011.01.008

17. Maes A, Weiland L, Sandersen C, Gauthys F, Backer PD, Croubels S. Determination of lidocaine and its two N-desethylated metabolites in dog and horse plasma by high-performance liquid chromatography combined with electrospray ionization tandem mass spectrometry. J Chromatogr B. 2007;852(1–2):180–187. doi:10.1016/j.jchromb.2007.01.010

18. Oni G, Brown S, Burrus C, et al. Effect of 4% topical lidocaine applied to the face on the serum levels of lidocaine and its metabolite, monoethylglycine xylide | aesthetic surgery journal | oxford academic. Aesthetic Surg J. 2010;30(6):853–858. doi:10.1177/1090820X10386944

19. Libby P, Buring JE, Badimon L, et al. Atherosclerosis. Nat Rev Dis Primers. 2019;5(1):56. doi:10.1038/s41572-019-0106-z

20. Pueksa M, Gorham LM, Ma B, et al. In vitro metabolism of simvastatin in humans: identification of metabolizing enzymes and effect of the drug on hepatic P450s. Drug Metab Dispos. 1997;25(10):1191–1199.

21. Yuan W, Yi J, Yun X, Wang M, Dai Y, Xia Y. Co-administration of simvastatin or lovastatin alters the pharmacokinetic profile of simvastatin in rats through cytochrome P450-mediated pathways. Life Sci. 2018;209:228–235. doi:10.1016/j.lfs.2018.08.012

22. Zhou X-Y, Hu X-X, Wang C-C, et al. Enzymatic activities of CYP3A4 alleric variants on quinine 3-hydroxylation in vitro. Front Pharmacol. 2019;10:6. doi:10.3389/fphar.2019.00591

23. Fang P, Tang PF, Xu RA, et al. Functional assessment of CYP3A4 alleric variants on lidocaine metabolism in vitro. Drug Des Devel Ther. 2017:11:3503–3510. doi:10.2147/DDDT.S152366

24. FDA. FDA Guidance for Industry Drug Interaction Studies - Study Design, Data Analysis, and Implications for Dosing and Labeling; 2006.

25. He J, Ping F, Xiang Z, et al. Inhibitory effect of celecoxib on agomelatine metabolism in vitro and in vivo. Drug Des Devel Ther. 2018;12:513–519. doi:10.2147/DDDT.S160316

26. Lin QM, Pang NH, Li YH, et al. Investigation of the effects of axitinib on the pharmacokinetics of loperamide and its main metabolite N-demethylated loperamide in rats by UPLC-MS/MS. Chem Biol Interact. 2019;317:108744. doi:10.1016/j.cbi.2019.108744

27. Shen L, Wang J, Yi Y, et al. Inhibitory effect of isavuconazole, ketoconazole and voriconazole on the pharmacokinetics of methadone in vivo and in vitro. Drug Test Anal. 2018;11(4):595–600. doi:10.1002/dta.2534

28. Lin QM, Pang NH, Li YH, et al. Investigation of the effects of axitinib on the pharmacokinetics of loperamide and its main metabolite N-demethylated loperamide in rats by UPLC-MS/MS. Chem Biol Interact. 2019;317:108744. doi:10.1016/j.cbi.2019.108744

29. FDA. Guidance for industry: bioanalytical method validation; 2018. Available from: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/bioanalytical-method-validation-guidance-industry. Accessed April 14, 2020.

30. EMEA. Committee for medicinal products for human use, guideline on bioanalytical method validation; 2011. Available from: https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-bioanalytical-method-validation_en.pdf. Accessed April 14, 2020.

31. Zhou D, Andersson TB, Grimm SW. In vitro evaluation of potential drug-drug interactions with ticagrelor: cytochrome P450 reaction phenotyping, inhibition, induction, and differential kinetics. Drug Metab Dispos. 2011;39(4):703. doi:10.1124/dmd.110.037143

32. Ekins S, Ring BJ, Grace J, Mrobie-Belle DJ, Wrighton SA. Present and future in vitro approaches for drug metabolism. J Pharmacol Toxicol Methods. 2000;44(1):313–324. doi:10.1016/S1056-8719(00)00011-6

33. Gao J, Ren H, Feng Z, et al. Effects of multidose simvastatin co-administration on pharmacokinetic profile of apatinib in rats by UPLC-MS/MS. Xenobiotica. 2020;1–21. doi:10.1080/00498254.2020.1740952

34. Orlando R, Piccoli P, De Martin S, et al. Cytochrome P450 1A2 is mediated primarily by CYP3A, and not CYP2D6. J Clin Pharmacol. 2008;48(9):1008–1016. doi:10.11736/jclinph.2008.042516408X284664
